Literature DB >> 6137620

Cortical cholinergic deficit in mentally impaired Parkinsonian patients.

R H Perry, B E Tomlinson, J M Candy, G Blessed, J F Foster, C A Bloxham, E R Perry.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6137620     DOI： 10.1016/s0140-6736(83)92317-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  10 in total

1.  Motor cortex inhibitory circuits in dementia with Lewy bodies and in Alzheimer's disease.

Authors:  R Nardone; A Bratti; F Tezzon
Journal:  J Neural Transm (Vienna)       Date:  2006-10-06       Impact factor: 3.575

Review 2.  A risk-benefit assessment of drugs used in the management of Parkinson's disease.

Authors:  I Y Bodagh; D R Robertson
Journal:  Drug Saf       Date:  1994-08       Impact factor: 5.606

3.  Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions?

Authors:  B Pillon; B Dubois; G Cusimano; A M Bonnet; F Lhermitte; Y Agid
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-02       Impact factor: 10.154

Review 4.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

5.  Reductions in parietal and temporal cerebral metabolic rates for glucose are not specific for Alzheimer's disease.

Authors:  M B Schapiro; P Pietrini; C L Grady; M J Ball; C DeCarli; A Kumar; J A Kaye; J V Haxby
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-08       Impact factor: 10.154

6.  Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease.

Authors:  E K Perry; M Curtis; D J Dick; J M Candy; J R Atack; C A Bloxham; G Blessed; A Fairbairn; B E Tomlinson; R H Perry
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-05       Impact factor: 10.154

7.  Diffuse Lewy body disease. Neuropathological and biochemical studies of six patients.

Authors:  D W Dickson; P Davies; R Mayeux; H Crystal; D S Horoupian; A Thompson; J E Goldman
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

8.  Somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with Parkinson's disease and its relation to dementia.

Authors:  J Jolkkonen; H Soininen; T Halonen; A Ylinen; V Laulumaa; M Laakso; P Riekkinen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-12       Impact factor: 10.154

9.  Clinical characteristics of cognitive impairment in patients with Parkinson's disease and its related pattern in 18 F-FDG PET imaging.

Authors:  Lei Wu; Feng-Tao Liu; Jing-Jie Ge; Jue Zhao; Yi-Lin Tang; Wen-Bo Yu; Huan Yu; Tim Anderson; Chuan-Tao Zuo; Ling Chen; Jian Wang
Journal:  Hum Brain Mapp       Date:  2018-07-12       Impact factor: 5.038

10.  Cerebral Metabolic Differences Associated with Cognitive Impairment in Parkinson's Disease.

Authors:  Yilin Tang; Jingjie Ge; Fengtao Liu; Ping Wu; Sisi Guo; Zhenyang Liu; Yixuan Wang; Ying Wang; Zhengtong Ding; Jianjun Wu; Chuantao Zuo; Jian Wang
Journal:  PLoS One       Date:  2016-04-11       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.